Reistone Biopharma
PrivateLast Round
Series A
May 9, 2022
Est. Valuation
$400M
Total Funding Raised
$100M
Company Overview
Reistone Biopharma is a biopharmaceutical company that develops novel medicines for autoimmune and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Reistone Biopharma Comparables
Compare Reistone Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lynk Pharmaceuticals | 88% | |
| 杭州高光制药股份有限公司 | 81% | |
| Aclaris Therapeutics | 79% |
For institutional investors. Book with your work email.
Reistone Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 9, 2022 | ||||
| Corporate Funding | Jan 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Reistone Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 清科产投 | Series A |
| Huagai Capital | Series A |
| Hanne Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 3, 2025
Monthly visitors increased 555% MoM.
- May 9, 2022
$100M round led by Huagai Capital
For institutional investors. Book with your work email.
Reistone Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Reistone Biopharma's valuation, stock price, and market status.
Is Reistone Biopharma a public or private company?
Reistone Biopharma is a private company.
What is the current stock price of Reistone Biopharma?
Reistone Biopharma is a private company, so its shares have no public market price. Caplight tracks Reistone Biopharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Reistone Biopharma worth (valuation)?
Reistone Biopharma's valuation is estimated at $400.0M based on funding round data.
Can I buy Reistone Biopharma stock?
Reistone Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Reistone Biopharma's last funding round?
Reistone Biopharma's most recent funding round was Series A on May 9, 2022.
Who are the main investors in Reistone Biopharma?
Key investors in Reistone Biopharma include Huagai Capital.
Will Reistone Biopharma IPO soon?
No public IPO plans have been announced for Reistone Biopharma.
How can I track Reistone Biopharma secondary market activity?
Caplight tracks bids, offers, and trades in Reistone Biopharma's shares on secondary markets.